Larimar Therapeutics Inc Stock Ownership - Who owns Larimar Therapeutics?

Insider buying vs selling

Have Larimar Therapeutics Inc insiders been buying or selling?
James E. FlynnDirector2024-02-161,430,205$8.74
James E. FlynnDirector2024-02-161,430,206$8.74
James E. FlynnDirector2024-02-161,430,206$8.74
Frank E. ThomasDirector2024-02-142,000$11.00
Gopi ShankarChief Development Officer2023-12-075,000$3.73

1 of 1

LRMR insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when LRMR insiders and whales buy or sell their stock.

LRMR Shareholders

What type of owners hold Larimar Therapeutics Inc stock?
James E. Flynn45.12%28,789,915$212.47MInsider
Deerfield Management Company LP Series C33.28%21,231,974$156.69MInstitution
Peter Barrett16.11%10,276,057$75.84MInsider
Bruce Booth16.10%10,270,758$75.80MInsider
Ra Capital Management LP9.48%6,045,351$44.61MInstitution
Janus Henderson Group PLC6.30%4,020,965$29.67MInstitution
Blue Owl Capital Holdings LP6.26%3,994,468$29.48MInstitution
Goldman Sachs Group Inc5.36%3,417,598$25.22MInstitution
Deerfield Partners LP4.35%2,777,777$20.50MInsider
Vanguard Group Inc3.71%2,367,701$17.47MInstitution

1 of 3

LRMR vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
LRMR53.90%46.10%Net Buying
URGN73.08%26.92%Net BuyingNet Selling
RNAC54.76%45.24%Net BuyingNet Buying
VYGR54.30%45.70%Net SellingNet Selling
TVTX60.31%39.69%Net SellingNet Selling

Larimar Therapeutics Stock Ownership FAQ

Who owns Larimar Therapeutics?

Larimar Therapeutics (NASDAQ: LRMR) is owned by 99.65% institutional shareholders, 85.22% Larimar Therapeutics insiders, and 0.00% retail investors. James E. Flynn is the largest individual Larimar Therapeutics shareholder, owning 28.79M shares representing 45.12% of the company. James E. Flynn's Larimar Therapeutics shares are currently valued at $209.30M.

If you're new to stock investing, here's how to buy Larimar Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.